Transcept Pharmaceuticals to Report Second Quarter 2010 Results and Host Conference Call on August 9, 2010
POINT RICHMOND, Calif., July 27 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that it plans to release second quarter 2010 financial results on August 9, 2010, after the close of the market. At 5:00 p.m. Eastern Time, Transcept management will host a webcast and teleconference to discuss these results.
Conference Call Information |
||
Date: Monday, August 9, 2010 |
||
Time: 5:00 p.m. EDT |
||
Dial-in (U.S.): 877-638-4558 |
||
Dial-in (International): 914-495-8537 |
||
A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at www.transcept.com. A replay of this webcast will be available on the website beginning shortly after the conclusion of the call through September 17, 2010.
A telephone replay of the conference call will be available beginning shortly after the conclusion of the call through August 13, 2010. The replay telephone number is 800-642-1687 (U.S.) or 706-645-9291 (International), replay passcode: 89393318.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The most advanced Transcept product candidate is Intermezzo® (zolpidem tartrate sublingual tablet), for which a New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in September 2008 seeking approval as a prescription sleep aid for use in the middle of the night at the time a patient awakens and has difficulty returning to sleep. In October 2009, Transcept received a Complete Response Letter from the FDA on the Intermezzo® NDA and is working to respond to issues raised in the letter. Transcept and Purdue Pharmaceutical Products, L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. Transcept is also developing TO-2061, an ultra low dose ondansetron adjunctive therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with SSRIs. Transcept plans to begin a Phase 2 study of TO-2061 in 2011. For further information, please visit the company's website at: www.transcept.com.
Forward Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release are forward-looking statements. An example of such a statement is our plan to begin a Phase 2, double-blind, placebo-controlled study of TO-2061 in 2011. Transcept may not actually carryout this plan. Various important factors could cause actual events to differ materially from the forward-looking statements that Transcept makes, include the outcomes from planned Phase 1 studies of TO-2061 and discussions with the FDA about our plan to move forward with the Phase 2 study; dependence on third parties to manufacture TO-2061 and carry-out the planned study; our success in seeking approval for Intermezzo®, our lead product candidate, and the business of Transcept generally. These and other risks are described in greater detail in the "Risk Factors" section of Transcept periodic reports filed with the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments Transcept may enter into or make. Transcept does not assume any obligation to update any forward-looking statements, except as required by law.
Contact: |
|
Transcept Pharmaceuticals, Inc. |
|
Greg Mann |
|
Director, Corporate Communications |
|
(510) 215-3567 |
|
SOURCE Transcept Pharmaceuticals, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article